Phenotypic analysis of human lymphocyte sub-populations post treatment with pi-water (MRN-100) (Meeting abstract).

Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Phenotypic analysis of human lymphocyte sub-populations post treatment with pi-water (MRN-100) (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 38:A801 1997. Unique Identifier : AIDSLINE ICDB/98637801
Ghoneum M; Namatalla G; Kijima Y; Drew University of Med. and Sc., 1621 E 120 Street, Los Angeles,; CA

Abstract: We have recently demonstrated that pi-water (MRN-100) is a potent biological response modifier (BRM) that enhances Natural Killer (NK) cell activity in vivo. The MRN-100 is an iron base compound derived from bivalent and trivalent ferrates. In this study a phenotypic analysis of human lymphocyte sub-populations post treatment with pi-water was made. Five healthy control individuals were given pi-water (50 cc) daily by mouth for 1 month, and changes of lymphocyte sub-populations was examined by FAScan using appropriate monoclonal antibodies for CD4+,CD8+ cells, B cells, total NK (CD16+ and CD56+) cells and NK sub populations: NKHT3+ cells and NKHT3- cells. Results post-treatment were compared with base line values and showed that: (1) No significance changes in the total and the percentages of CD4+ and CD8+ cells and B cells. (2) Remarkable increase in the total (134%); and percentage of NK cells (142%). (3) 1.6 fold increase in the total and percentage of NK HT3+ cells and (4) 1.2 fold increase of NKHT3- cells. We conclude that the increase in NK cell sub-populations post treatment with pi-water may represent one mechanism by which this new BRM enhances NK cell activity.

Keywords: B-Lymphocytes/DRUG EFFECTS Biological Response Modifiers/*PHARMACOLOGY CD4-Positive T-Lymphocytes/DRUG EFFECTS CD8-Positive T-Lymphocytes/DRUG EFFECTS Human Killer Cells, Natural/*DRUG EFFECTS Lymphocyte Count/*DRUG EFFECTS ABSTRACT
980228
M9820768

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .